









Markets
/
Stocks
/
nasdaq-imvt
/

Immunovant Inc

IMVT

15.110USD

-0.180-1.18%

Close 09/17, 16:00（ET）Quotes delayed by 15 min

2.58BMarket Cap

LossP/E TTM



Immunovant Inc

15.110

-0.180-1.18%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

196 / 507

Overall Ranking

349 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 16 analysts

Buy

Current Rating

39.667

Target Price

+159.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 96.17.

Overvalued

The company’s latest PE is -5.32, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 194.27M shares, decreasing 1.06% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 7.01M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -5.32, which is 4.72% below the recent high of -5.57 and -34.88% above the recent low of -7.18.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 196/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.25, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Immunovant Inc is 44.50, with a high of 57.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 16 analysts

Buy

Current Rating

39.667

Target Price

+159.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Immunovant Inc

IMVT

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.43, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 16.82 and the support level at 13.94, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.63

Change

-0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.076

Neutral

RSI(14)

43.812

Neutral

STOCH(KDJ)(9,3,3)

13.123

Sell

ATR(14)

0.833

High Vlolatility

CCI(14)

-62.384

Neutral

Williams %R

77.778

Sell

TRIX(12,20)

0.111

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

15.778

Sell

MA10

16.112

Sell

MA20

15.622

Sell

MA50

16.254

Sell

MA100

15.803

Sell

MA200

18.563

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 113.56%, representing a quarter-over-quarter decrease of 0.77%. The largest institutional shareholder is The Vanguard, holding a total of 7.01M shares, representing 4.02% of shares outstanding, with 11.19% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Roivant Sciences Ltd.

96.65M

Fidelity Management & Research Company LLC

16.12M

+31.52%

Deep Track Capital LP

9.50M

+58.33%

The Vanguard Group, Inc.

Star Investors

6.92M

+3.78%

T. Rowe Price Investment Management, Inc.

5.89M

+15.20%

Baker Bros. Advisors LP

5.46M

+219.57%

Armistice Capital LLC

4.50M

+16.26%

BlackRock Institutional Trust Company, N.A.

4.75M

+4.20%

State Street Global Advisors (US)

3.09M

+14.44%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.18, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.